Gaurav Aggarwal's most recent trade in Unicycive Therapeutics Inc was a trade of 652,900 Common Stock done . Disclosure was reported to the exchange on Aug. 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 25 Aug 2025 | 652,900 | 1,789,915 | - | - | Common Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 25 Aug 2025 | 3,199 | 0 | - | - | Series A-2 Prime Preferred Stock | |
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 21,200 | 39,200 | - | - | Stock Options | |
| Geron Corp. | Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 18 Feb 2025 | 1,400,000 | 11,370,152 | - | - | Common Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Feb 2025 | 686 | 3,119 | - | - | Series A-2 Prime Preferred Stock | |
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 09 Oct 2024 | 5,500,000 | 9,970,152 | - | - | Common Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 09 Oct 2024 | 2,695 | 3,885 | - | - | Series A-2 Prime Preferred Stock | |
| Geron Corp. | Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Geron Corp. | Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 1,970 | 1,970 (0%) | 0% | 0 | Common Stock | |
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 18,621,655 | 18,621,655 | - | - | Tranche C Warrants (right to buy) | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 13,429,000 | 13,429,000 | - | - | Series A-2 Preferred Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 12,802,388 | 12,802,388 | - | - | Tranche A Warrants (right to buy) | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 11,638,534 | 11,638,534 | - | - | Tranche B Warrants (right to buy) | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 3,470,152 | 3,470,152 | - | - | Common Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | 11 Jul 2023 | 8,077 | 0 | - | - | Series A-1 Preferred Stock | ||
| Unicycive Therapeutics Inc | Gaurav Aggarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 8,077 | 8,077 | - | - | Series A-1 Convertible Preferred Stock |